Dr. Reddy’s Laboratories shares rose 4% after Nuvama upgraded its rating to 'buy,' citing proactive strategies to mitigate the impact of Revlimid’s patent expiry in 2026. The brokerage set a target price of Rs 1,553, reflecting a 15% upside. Dr. Reddy’s is also expanding its portfolio with new drug launches and growth in core markets like India and China.
